Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ICLR's Cash to Debt is ranked higher than
94% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.91 vs. ICLR: No Debt )
ICLR' s 10-Year Cash to Debt Range
Min: 0.85   Max: No Debt
Current: No Debt

Equity to Asset 0.65
ICLR's Equity to Asset is ranked higher than
72% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ICLR: 0.65 )
ICLR' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.77
Current: 0.65

0.53
0.77
Interest Coverage 94.07
ICLR's Interest Coverage is ranked higher than
65% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. ICLR: 94.07 )
ICLR' s 10-Year Interest Coverage Range
Min: 17.93   Max: 9999.99
Current: 94.07

17.93
9999.99
F-Score: 6
Z-Score: 6.46
M-Score: -2.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.69
ICLR's Operating margin (%) is ranked higher than
82% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ICLR: 8.69 )
ICLR' s 10-Year Operating margin (%) Range
Min: 2.27   Max: 12.11
Current: 8.69

2.27
12.11
Net-margin (%) 7.36
ICLR's Net-margin (%) is ranked higher than
82% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. ICLR: 7.36 )
ICLR' s 10-Year Net-margin (%) Range
Min: 1.76   Max: 13.44
Current: 7.36

1.76
13.44
ROE (%) 15.27
ICLR's ROE (%) is ranked higher than
87% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ICLR: 15.27 )
ICLR' s 10-Year ROE (%) Range
Min: 3.39   Max: 22.48
Current: 15.27

3.39
22.48
ROA (%) 9.73
ICLR's ROA (%) is ranked higher than
90% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. ICLR: 9.73 )
ICLR' s 10-Year ROA (%) Range
Min: 2.31   Max: 16.82
Current: 9.73

2.31
16.82
ROC (Joel Greenblatt) (%) 70.79
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. ICLR: 70.79 )
ICLR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.96   Max: 57.6
Current: 70.79

11.96
57.6
Revenue Growth (%) 11.20
ICLR's Revenue Growth (%) is ranked higher than
84% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. ICLR: 11.20 )
ICLR' s 10-Year Revenue Growth (%) Range
Min: -14.6   Max: 54.5
Current: 11.2

-14.6
54.5
EBITDA Growth (%) 8.70
ICLR's EBITDA Growth (%) is ranked higher than
78% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ICLR: 8.70 )
ICLR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 36.6
Current: 8.7

0
36.6
EPS Growth (%) 4.60
ICLR's EPS Growth (%) is ranked higher than
74% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ICLR: 4.60 )
ICLR' s 10-Year EPS Growth (%) Range
Min: -34.2   Max: 54.4
Current: 4.6

-34.2
54.4
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ICLR Guru Trades in Q3 2013

Jim Simons 495,160 sh (+74.87%)
Ron Baron 1,280,000 sh (+25.15%)
RS Investment Management 470,360 sh (+9.27%)
Jean-Marie Eveillard 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 210,200 sh (-21.38%)
Steven Cohen 9,031 sh (-85.02%)
» More
Q4 2013

ICLR Guru Trades in Q4 2013

Paul Tudor Jones 200,000 sh (New)
Steven Cohen 219,406 sh (+2329.48%)
Jim Simons 830,860 sh (+67.8%)
Ron Baron 1,430,000 sh (+11.72%)
RS Investment Management 500,960 sh (+6.51%)
Chuck Royce 210,200 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
» More
Q1 2014

ICLR Guru Trades in Q1 2014

Caxton Associates 15,000 sh (New)
Chuck Royce 210,200 sh (unchged)
Ron Baron 1,430,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 195,389 sh (-10.95%)
Jim Simons 712,260 sh (-14.27%)
» More
Q2 2014

ICLR Guru Trades in Q2 2014

Ron Baron 1,530,000 sh (+6.99%)
Chuck Royce 210,200 sh (unchged)
Jean-Marie Eveillard Sold Out
Caxton Associates Sold Out
Jim Simons 613,600 sh (-13.85%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Sold Out $37.92 - $48.97 $ 56.7332%0
Ron Baron 2013-09-30 Add 25.15%0.05%$36.24 - $40.67 $ 56.7347%1280000
Ron Baron 2013-06-30 Add 24.31%0.04%$29.2 - $36.22 $ 56.7372%1022800
Meridian Funds 2013-03-31 Reduce -33.19%0.17%$27.25 - $32.91 $ 56.7390%308000
Ron Baron 2013-03-31 New Buy0.15%$27.25 - $32.91 $ 56.7390%822800
Meridian Funds 2012-12-31 Reduce -28.22%0.16%$23.46 - $28.54 $ 56.73115%461000
Meridian Funds 2012-06-30 Add 24.87%0.1%$20.51 - $23.23 $ 56.73160%642200
Meridian Funds 2012-03-31 Add 25.16%0.06%$17.06 - $22.01 $ 56.73199%514300
Jean-Marie Eveillard 2011-09-30 Add 36.36%$16.5 - $25.21 $ 56.73175%15000
Meridian Funds 2011-06-30 New Buy0.24%$21.18 - $25.92 $ 56.73136%351000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Icon PLC

Baron Funds Comments on ICON PLC - Jun 10, 2013

Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.

From Baron Funds’ first quarter 2013 commentary.
Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 26.50
ICLR's P/E(ttm) is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 26.50 )
ICLR' s 10-Year P/E(ttm) Range
Min: 4.37   Max: 78.79
Current: 26.5

4.37
78.79
P/B 3.60
ICLR's P/B is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. ICLR: 3.60 )
ICLR' s 10-Year P/B Range
Min: 0.46   Max: 5.55
Current: 3.6

0.46
5.55
P/S 2.00
ICLR's P/S is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ICLR: 2.00 )
ICLR' s 10-Year P/S Range
Min: 0.58   Max: 2.14
Current: 2

0.58
2.14
PFCF 36.60
ICLR's PFCF is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 36.60 )
ICLR' s 10-Year PFCF Range
Min: 5.14   Max: 600.13
Current: 36.6

5.14
600.13
EV-to-EBIT 20.53
ICLR's EV-to-EBIT is ranked higher than
84% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. ICLR: 20.53 )
ICLR' s 10-Year EV-to-EBIT Range
Min: 1.4   Max: 50.5
Current: 20.53

1.4
50.5
PEG 16.19
ICLR's PEG is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 16.19 )
ICLR' s 10-Year PEG Range
Min: 0.06   Max: 11.49
Current: 16.19

0.06
11.49
Shiller P/E 41.70
ICLR's Shiller P/E is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 41.70 )
ICLR' s 10-Year Shiller P/E Range
Min: 6.36   Max: 41.7
Current: 41.7

6.36
41.7
Current Ratio 1.59
ICLR's Current Ratio is ranked higher than
56% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ICLR: 1.59 )
ICLR' s 10-Year Current Ratio Range
Min: 1.48   Max: 3.61
Current: 1.59

1.48
3.61
Quick Ratio 1.59
ICLR's Quick Ratio is ranked higher than
60% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ICLR: 1.59 )
ICLR' s 10-Year Quick Ratio Range
Min: 1.48   Max: 3.61
Current: 1.59

1.48
3.61

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.80
ICLR's Price/Tangible Book is ranked higher than
65% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.18 vs. ICLR: 7.80 )
ICLR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 7.03
Current: 7.8

0.64
7.03
Price/DCF (Projected) 1.70
ICLR's Price/DCF (Projected) is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 1.70 )
ICLR' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 6.7
Current: 1.7

0.52
6.7
Price/Median PS Value 1.50
ICLR's Price/Median PS Value is ranked higher than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ICLR: 1.50 )
ICLR' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 1.54
Current: 1.5

0.45
1.54
Price/Graham Number 3.00
ICLR's Price/Graham Number is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 3.00 )
ICLR' s 10-Year Price/Graham Number Range
Min: 0.41   Max: 3.59
Current: 3

0.41
3.59
Earnings Yield (Greenblatt) 4.80
ICLR's Earnings Yield (Greenblatt) is ranked higher than
73% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. ICLR: 4.80 )
ICLR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 71.7
Current: 4.8

2
71.7
Forward Rate of Return (Yacktman) 5.54
ICLR's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. ICLR: 5.54 )
ICLR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.2   Max: 84.2
Current: 5.54

-16.2
84.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0NBW.UK
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It develops, manages, and analyses programs that support all stages of clinical development process - from compound selection to Phase I-IV clinical studies. The Company provides its customers clinical research services which include: clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services.
» More Articles for NAS:ICLR

Headlines

Articles On GuruFocus.com
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
ICON publie ses orientations financières pour l’année 2009 et les mises à jour des orientations Jan 09 2009 
Resumen: ICON presenta previsiones financieras para 2009 y actualiza las de 2008 Jan 09 2009 
Samenvatting: ICON publiceert cijfers voor 2009 en werkt cijfers 2008 bij Jan 09 2009 
ICON veröffentlicht Ergebniserwartung für 2009 und aktualisiert Erwartung für 2008 (NASDAQ:ICLR) Jan 09 2009 
ICON Issues Financial Guidance for 2009 and Updates Guidance for 2008 (NASDAQ:ICLR) (ISIN:IE00057112 Jan 09 2009 
Riassunto: ICON rende noti gli orientamenti finanziari per il 2009 e un aggiornamento degli orientam Jan 09 2009 


More From Other Websites
Why the Earnings Streak Will Continue for ICON Public Limited (ICLR) Sep 23 2014
Greater Expectations Sep 19 2014
ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for... Sep 19 2014
ICON Plc Announces Completion of $40 Million Share Buyback and a Further Share Buyback Program for... Sep 19 2014
Taking Stock: Baird’s Skorney on Developing ‘Hot Drug’ Sep 10 2014
Medidata and ICON Join Forces to Bring New Productivity to Capturing Patient Voice in Clinical... Sep 10 2014
AMBS: Amarantus Investor Call Highlights Clinical And Commercial Milestones Sep 03 2014
iKang Healthcare Group, Inc. (KANG) Jumps: Stock Surges 10.1% Aug 26 2014
Is ICON Public Limited (ICLR) Stock a Solid Choice Right Now? Aug 25 2014
A Shift in Health-Care M&A Activity Aug 23 2014
Can ICON Public (ICLR) Stock Continue to Grow Earnings? Aug 12 2014
Air Methods (AIRM) Surges: Stock Adds 12.5% in Session Aug 11 2014
BioScrip (BIOS) in Focus: Stock Adds 8.2% in Session Aug 08 2014
Charles River Laboratories (CRL) Jumps: Stock Moves 5% Higher Aug 08 2014
ICON: Pfizer and Roche Join ADDPLAN DF Consortium Aug 01 2014
ICON plc (ICLR) Worth Watching: Stock Rises 8.8% Jul 31 2014
Indexes Close Mixed After Mixed Data, Fed Statement Jul 30 2014
ICON PLC Earnings Call scheduled for 8:30 am ET today Jul 30 2014
Q2 2014 ICON PLC Earnings Release - Time Not Supplied Jul 30 2014
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK